Highly Regular Laser-Induced Periodic Surface Structures on Titanium Thin Films for Photonics and Fiber Optics.

Modern photonic devices demand low-cost, scalable methods for creating periodic patterns over diverse surfaces including nonplanar and tipped ones, the examples of which can be readily found in fiber optics. Laser-induced periodic surface structures (LIPSS) offer an attractive route for fabricating such patterns in a single-step straightforward procedure, where the temporal and spatial locality of the self-interference effects ensure robustness against variations of the laser processing parameters. In this work, we show the LIPSS-assisted oxidation of thin titanium films by near-IR femtosecond laser pulses as a promising technology for the production of regular gratings consisting of rutile ridges.

Raman Lasing and Transverse Mode Selection in a Multimode Graded-Index Fiber with a Thin-Film Mirror on Its End Face.

Multimode fibers are attractive for high-power lasers if transverse modes are efficiently controlled. Here, a dielectric thin-film mirror (R~20%) is micro-fabricated on the central area of the end face of a 1 km multimode 100/140 µm graded-index fiber and tested as the output mirror of a Raman laser with highly multimode (M~34) 940 nm diode pumping. In the cavity with highly reflective input FBG, Raman lasing of the Stokes wave at 976 nm starts at the threshold pump power of ~80 W.

SPECIFICS OF PRESCRIBING ANTIRETROVIRAL DRUGS IN THE TREATMENT OF HIV INFECTION.

HIV infection is one of the most acute problems of our time, characterized by slow development, prolonged course, and numerous clinical manifestations. Currently, there is a large number of drugs acting on different processes of human immunodeficiency virus replication, which constitute the group of highly active antiretroviral therapy (HAART). This article shows a theoretical review of modern HAART and analyzes the prescribed treatment regimens for patients with HIV infection.

Analytical and functional similarity of biosimilar Elizaria® with eculizumab reference product.

A recombinant humanized monoclonal antibody (mAb) Eculizumab, C5-complement cascade inhibitor, is an important treatment of complement-based diseases recommended by international guidelines. Elizaria® Drug Product (DP), developed by IBC Generium, Russia, is the world's first registered biosimilar of eculizumab (Soliris®, Alexion Pharmaceuticals). Using sensitive state-of-the-art analytical techniques extensive similarity assessment has been conducted to demonstrate the structural and functional similarity of original Soliris® (Eculizumab Reference Product, RP) and the biosimilar Elizaria®, focusing on the physicochemical and biological quality attributes, including those known to affect the mechanisms of action.

Physicochemical and Biological Characterization of rhC1INH Expressed in CHO Cells.

The disfunction or deficiency of the C1 esterase inhibitor (C1INH) is associated with hereditary or acquired angioedema (HAE/AAE), a rare life-threatening condition characterized by swelling in the skin, respiratory and gastrointestinal tracts. The current treatment options may carry the risks of either viral infection (plasma-derived Berinert) or immune reaction (human recombinant C1INH from rabbit milk, Ruconest). This study describes the physicochemical and biological characterization of a novel recombinant human C1 esterase inhibitor (rhC1INH) from Chinese hamster ovary (CHO) cells for the treatment of hereditary angioedema compared to the marketed products Berinert and Ruconest.